Phase 3 Schizophrenia Trial, Recruiting NCT07114874 Sponsor: Neurocrine Biosciences Condition: Schizophrenia
Back to Schizophrenia

Phase 3 Schizophrenia Trial, Recruiting

NCT07114874
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with schizophrenia as their primary condition
  • People who are able to stop taking certain medications before the study begins, including antipsychotics, if they are currently taking any
  • People who have a stable, secure living situation

Who may not be able to join:

  • People who have a known allergic reaction or sensitivity to any ingredient in the study drug, NBI-1117568
  • People who have an unstable or poorly managed ongoing medical condition or chronic illness
  • People whom the trial doctor considers to be at immediate risk of harming themselves or others
  • People who have been diagnosed with a moderate or severe problem with substance use (other than nicotine or caffeine dependence) within the six months before screening
  • People who test positive for alcohol or disallowed substances at the time of screening
  • People who have a history of not following study rules in previous clinical research, or whom the trial doctor believes would not be able to follow the requirements of this study

Important: Always verify eligibility with the trial site directly before applying.

Note: There may be additional criteria not listed here. The trial site will assess all requirements in full.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Clinical Development Lead, Neurocrine Biosciences

Phone: 877-641-3461

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Neurocrine Biosciences
Registry
ClinicalTrials.gov
Start date
11 July 2025
Est. completion
1 December 2031

Where this trial is recruiting

🇧🇬 Bulgaria 🇷🇴 Romania 🇷🇸 Serbia 🇺🇸 United States

Primary endpoints

Number of Participants with Treatment-emergent Adverse Events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov